Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension

International Heart Journal

Volumn 50, Issue 1, 2009, Pages 85-93

  Minami, Junichi ^a   Furukata, Satoshi ^a   Ishimitsu, Toshihiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Combination; Diuretic; Losartan; Peroxisome proliferator activated receptor ; Telmisartan; Uricosuric action

Indexed keywords

AMLODIPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRENDIPINE; TRIACYLGLYCEROL; URIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPID METABOLISM; LONG TERM CARE; MALE; MORNING DOSAGE; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 61749103568     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.85     Document Type: Article

References (17)

1. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
2. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29: S1-106.
3. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-87.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
5. Benson SC, Pershadsingh HA, Ho CI, et al. Identilication of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
6. Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). Int Heart J 2007; 48: 637-47.
7. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-53.
8. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorolhiazide in patients with hypertension. Hypertension 1995; 26:112-7.
9. Lacourciére Y. Gil-Extremera B. Mueller O. Byrne M. Williams L. Efficacy and tolerability of fixeddose combinations of telmisartan plus HCTZ compared with losartan pias HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273-9.
10. Neutel JM, Littlejohn TW, Chrysant SG, Singh A; Telmisartan Study Group. Telmisartan/Hydrochlorothiazid in comparison with losartan/ hydrochlorothiazide in managing patients with mild-tomoderate hypertension. Hypertens Res 2005; 28: 555-63.
11. Lacourciére Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochloro-thiazide 50/12.5 mg in mild to moderate essential hypertension- pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005; 27: 1795-805.
12. Borai A, Livingstone C, Ferns GA. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007; 44: 324-42. (Review)
13. Yamazaki T, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J 2007; 48: 715-24.
14. Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-51.
15. Minami J, Ishimitsu T, Matsuoka H. Pretreaunent plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21: 10-3.
16. Kato J, Eto T. Diuretics in the LIFE study. Lancet 2004; 364: 413.
17. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-64.